Interim Report April – September 2020
Another quarter with more then 30 percent growthCEO’s comments The second quarter of 2020/21 was another quarter with good growth for EQL Pharma. Sales for the quarter amounted to SEK 24.2 million, an increase of 36%. During the quarter, an order for healthcare consumables, totalling SEK 8 million, was received from a Hospital region. Around 3 MSEK of this order was invoiced during the quarter and the remaining part will be invoiced during the third quarter. The corona epidemic has had a minor impact on our company, where some products sell more than usual due to stock-outs for our